Tienopiridinas y su rol en el tratamiento del síndrome coronario agudo.

Yanier Coll Muñoz

Resumen


Gracias a la comprensión del síndrome coronario agudo como un proceso aterotrombótico, la plaqueta ha asumido un papel preponderante en la medicina cardiovascular. Actualmente, los esfuerzos se centran en la mejora de los tratamientos antiplaquetarios en uso, con el objetivo de mejorar su efectividad y su seguridad. Este artículo revisa el papel de las tienopiridinas en el tratamiento del síndrome coronario agudo, así como las diferencias en los aspectos farmacocinéticos y farmacodinámicos; además, se comentan las nuevas aproximaciones terapéuticas.


Palabras clave


tienopiridinas, agregación plaquetaria, síndrome coronario agudo

Texto completo:

HTML PDF

Referencias


a. Anderson JL, Adams CD, Antman EM.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction.J Am Coll Cardiol.2007; 50(7):e1-e157.

Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al.Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST.Rev Esp Cardiol.2009; 62(3):e1-e47.

Raju NC, Eikelboom JW, Hirsh J.Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.Nat Clin Pract Cardiovasc Med.2008; 5(12):766-80.

Murugappa S, Kunapuli SP.The role of ADP receptors in platelet function.Front Biosci.2006; 11:1977-86.

Farid NA, Kurihara A, Wrighton SA.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.J Clin Pharmacol.2010; 50(2):126-42.

Tan JW, Guo KW.Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.Ann Acad Med Singapore.2010; 39(3):221-9.

Goodwin MM, Desilets RA, Willet CK.Thienopyridines in Acute Coronary Syndrome.The Annals of Pharmacotherapy.2011; 45(2):207-17.

Stiles MK, Dabbous OH, Fox KA.Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE).Heart Lung Circ.2008; 17(1):5-8.

Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, et al.Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.Xenobiotica.2009; 39(11):836-43.

Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al.Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.J Clin Pharmacol.2008; 48(4):475-84.

Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, et al.Pharmacodynamic assessment of platelet inhibition by prasugrel vs clopidogrel in the TRITON-TIMI 38 trial.Eur Heart J.2009; 30(14):1753-63.

Cuisset T, Cayla G.Aspirin and clopidogrel resistance: should we worry about?.Minerva Med.2010; 101(10):35-47.

Cairns JA, Eikelboom J.Clopidogrel resistance: more grist for the mill.J Am Coll Cardiol.2008; 51(20):1935-7.

Brandt JT, Payne CD, Wiviott SD.A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.Am Heart J.2007; 153(1):66.e9-16.

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH.Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): doubleblind, randomised controlled trial.Lancet.2009; 373(9665):723-31.

Wiviott SD, Trenk D, Frelinger AL, O Donoghue M, Neumann FJ, Michelson AD, et al.The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation– Thrombolysis in Myocardial Infarction 44 Trial.Circulation.2007; 116(25):2923-32.

Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD.ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.J Am Coll Cardiol.2008; 52(18):1502-17.

O Donoghue ML, Braunwald E, Antman EM, Sabina AM, Bates ER, Yoseph Rozenman Y, et al.Pharmacodynamic eff ect and clinical effi cacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.Lancet.2009; 374(9694):989-97.

Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al.Clopidogrel with or without omeprazole in coronary artery disease.N Engl J Med.2010; 363(20):1909-17.

Laine L, Hennekens C.Proton pump inhibitor and clopidogrel interaction: fact or fiction?.Am J Gastroenterol.2010; 105(1):34-41.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Furberg CD.ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines.Circulation.2010; 122:2619-33.

Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, et al.2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline).J Am Coll Cardiol.2011; 57:1920-59.

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al.Guía de práctica clínica sobre revascularización miocárdica.Rev Esp Cardiol.2010; 63(12):1485.e1-e76.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Eng J Med.2009; 361(11):1045-57.

Berger JS, Roe MT, Gibson CM.Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction.Am Heart J.2009; 158(6):998-1004.e1.


Enlaces refback

  • No hay ningún enlace refback.


FINLAY EN: google_acadmico_75 doaj_75 bvs_75 latindex_75medigraphy_75

FINLAY CERTIFICADA POR:

certificacin_citma_75

 Esta revista "no aplica" cargos por publicación en ninguna etapa del proceso editorial.

Facebook Twitter

Equipo Editorial

 

Dirección postal: Calle 51A y Avenida 5 de Septiembre Cienfuegos, Cuba Código postal: 55100.
http://www.revfinlay.sld.cu
Telefono: +53 43 516602. Telefax: +53 43 517733.
medisur@infomed.sld.cu
ISSN: 2221-2434
RNPS: 5129